Cancer Genetics Inc (NASDAQ:CGIX): Institutional Investor Sentiment Up to 1.11

July 14, 2018 - By Frank Plummer

Cancer Genetics, Inc. (NASDAQ:CGIX) Logo

Sentiment for Cancer Genetics Inc (NASDAQ:CGIX)

Cancer Genetics Inc (NASDAQ:CGIX) institutional sentiment increased to 1.11 in 2018 Q1. Its up 0.20, from 0.91 in 2017Q4. The ratio has improved, as 10 investment professionals increased or started new positions, while 9 sold and decreased their stock positions in Cancer Genetics Inc. The investment professionals in our partner’s database now hold: 2.70 million shares, down from 2.78 million shares in 2017Q4. Also, the number of investment professionals holding Cancer Genetics Inc in their top 10 positions decreased from 1 to 0 for a decrease of 1. Sold All: 3 Reduced: 6 Increased: 4 New Position: 6.

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker tests and services in the United States, India, and China. The company has market cap of $24.29 million. The Company’s tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. The companyÂ’s clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management.

The stock decreased 2.26% or $0.0202 during the last trading session, reaching $0.8754. About 124,683 shares traded. Cancer Genetics, Inc. (NASDAQ:CGIX) has declined 74.25% since July 14, 2017 and is downtrending. It has underperformed by 86.82% the S&P500.

Analysts await Cancer Genetics, Inc. (NASDAQ:CGIX) to report earnings on August, 13. They expect $-0.13 EPS, up 18.75 % or $0.03 from last year’s $-0.16 per share. After $-0.16 actual EPS reported by Cancer Genetics, Inc. for the previous quarter, Wall Street now forecasts -18.75 % EPS growth.

Perkins Capital Management Inc holds 1.43% of its portfolio in Cancer Genetics, Inc. for 963,600 shares. Diker Management Llc owns 64,365 shares or 0.04% of their US portfolio. Moreover, Granahan Investment Management Inc Ma has 0.03% invested in the company for 235,502 shares. The New York-based Hrt Financial Llc has invested 0.02% in the stock. Court Place Advisors Llc, a Maryland-based fund reported 10,000 shares.

Cancer Genetics, Inc. (NASDAQ:CGIX) Ratings Coverage

Ratings analysis reveals 50% of Cancer Genetics’s analysts are positive. Out of 2 Wall Street analysts rating Cancer Genetics, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $300 while the high is $6.0. The stock’s average target of $4.50 is 414.05% above today’s ($0.8754) share price. CGIX was included in 5 notes of analysts from January 16, 2018. The company was maintained on Tuesday, May 29 by H.C. Wainwright. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, June 27. Maxim Group downgraded the stock to “Hold” rating in Tuesday, April 3 report. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, January 16. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, February 6.

Cancer Genetics, Inc. (NASDAQ:CGIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.